BGM Group Calls New EGM After Cayman Regulator Rejects Prior Reverse Split Delegation
BGM sits 16% above its 52-week low of $0.25 on light trading volume (0.1× avg).
Summary
BGM Group is calling a new EGM on September 5, 2026, after the Cayman Islands regulator rejected the prior reverse split delegation. The new proposal fixes the ratio at 1-for-30 and increases authorized share capital to 5 billion class A ordinary shares, setting up potential massive dilution.
Key Events · Corporate Governance and Compliance · BGM
-
Cayman Regulator Rejects Prior Delegation
The Deputy Registrar of Companies of the Cayman Islands ruled that the board cannot be delegated authority to set the reverse split ratio, invalidating the resolutions passed at the July 9, 2026 EGM.
-
New EGM Called for September 5, 2026
Shareholders will vote on a fixed 1-for-30 reverse stock split, replacing the previously approved range of up to 1-for-50.
-
Massive Authorized Share Increase Proposed
Post-consolidation, authorized class A ordinary shares would increase to 5 billion with a par value of $0.003, creating significant headroom for future dilutive issuances.
-
Nasdaq Compliance at Stake
The reverse split is critical to address the Nasdaq bid price deficiency disclosed in the July 21, 2026 20-F; failure to regain compliance could lead to delisting.
Analysis · BGM · Life Sciences
The Cayman Islands Deputy Registrar of Companies rejected the board's authority to set the reverse split ratio, forcing BGM Group to call a new shareholder meeting on September 5, 2026. The new proposal fixes the ratio at 1-for-30 — a concrete number that removes the uncertainty of the prior 1-for-50 range. This is a necessary step to regain Nasdaq compliance after the bid price deficiency disclosed in the 20-F, but it also sets the stage for massive post-consolidation dilution: the authorized share capital jumps to 5 billion class A ordinary shares, giving the board ample room to issue shares after the reverse split. The stock trades at $0.291, so a 1-for-30 consolidation would theoretically lift the price to around $8.73, but the real risk is the enormous authorized share headroom that could be used for dilutive financings.
At the time of this filing, BGM was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $122.4M. The 52-week trading range was $0.25 to $11.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.